Which Clinical Factors Are Associated with the Post-Denosumab Size Reduction of Giant Cell Tumors? The Korean Society of Spinal Tumor (KSST) Multicenter Study 2023-02
ABC-like change, Campanacci grade III, and the longest tumor diameter might predict post-denosumab GCTB shrinkage in all patients, though shrinkage varies with lesion location and recurrence status. These factors could help clinicians tailor treatment strategies in different settings. Further research is needed to explore how clinical factors pharmacologically influence denosumab-induced GCTB shrinkage.
Authors
- Nicholas Matthew Bernthal (ORCID: https://orcid.org/0000-0003-3338-5878)
- J.T. Lee
- Min Wook Joo (ORCID: https://orcid.org/0000-0003-1348-2187)
- Wanlim Kim (ORCID: https://orcid.org/0000-0003-1544-7211)
- Moon-Sing Lee
- Yong-Suk Lee (ORCID: https://orcid.org/0000-0003-3646-749X)
- Sejun Park (ORCID: https://orcid.org/0000-0002-7647-4355)
- Yongsung Kim (ORCID: https://orcid.org/0000-0003-4203-9280)
- Jae Hwan Cho (ORCID: https://orcid.org/0000-0002-1178-9778)
Institutions
- University of California, Los Angeles (US)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- Seoul National University Bundang Hospital (KR)
- University of Ulsan (KR)
- The Catholic University of Korea St. Vincent's Hospital (KR)
- The Catholic University of Korea Incheon St. Mary's Hospital (KR)
- Sungkyunkwan University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Cancers
- Published
- 2025-06-24
- DOI
- https://doi.org/10.3390/cancers17132121
- Primary Topic
- Bone Tumor Diagnosis and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00